PML risk stratification using anti-JCV antibody index and L-selectin
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PML risk stratification using anti-JCV antibody index and L-selectin
Authors
Keywords
-
Journal
Multiple Sclerosis Journal
Volume 22, Issue 8, Pages 1048-1060
Publisher
SAGE Publications
Online
2015-10-03
DOI
10.1177/1352458515607651
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab
- (2015) Luisa M. Villar et al. ANNALS OF NEUROLOGY
- Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis
- (2015) Tomas Kalincik et al. ANNALS OF NEUROLOGY
- Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells
- (2015) Michela Spadaro et al. Journal of Neuroinflammation
- Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients
- (2015) Pabitra Basnyat et al. Multiple Sclerosis and Related Disorders
- Specific loss of cellular L-selectin on CD4+ T cells is associated with progressive multifocal leukoencephalopathy development during HIV infection
- (2014) Tilman Schneider-Hohendorf et al. AIDS
- Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy
- (2014) Tatiana Plavina et al. ANNALS OF NEUROLOGY
- No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation
- (2014) M. Capobianco et al. EUROPEAN JOURNAL OF NEUROLOGY
- MiR-126: a novel route for natalizumab action?
- (2014) Maria Meira et al. Multiple Sclerosis Journal
- Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
- (2014) Gary R Cutter et al. Multiple Sclerosis Journal
- Sorting out the risks in progressive multifocal leukoencephalopathy
- (2014) Leonard H. Calabrese et al. Nature Reviews Rheumatology
- A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification
- (2013) Peter Lee et al. JOURNAL OF CLINICAL VIROLOGY
- L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients
- (2013) N. Schwab et al. NEUROLOGY
- Risk factors for rare diseases can be risky to define: PML and natalizumab
- (2013) E. O. Major et al. NEUROLOGY
- Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
- (2012) Gary Bloomgren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neutralization Serotyping of BK Polyomavirus Infection in Kidney Transplant Recipients
- (2012) Diana V. Pastrana et al. PLoS Pathogens
- Positive correlation between Merkel cell polyomavirus viral load and capsid-specific antibody titer
- (2011) Diana V. Pastrana et al. MEDICAL MICROBIOLOGY AND IMMUNOLOGY
- Anti-JC virus antibodies: Implications for PML Risk Stratification
- (2010) Leonid Gorelik et al. ANNALS OF NEUROLOGY
- Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis
- (2010) Chen S Tan et al. LANCET NEUROLOGY
- BK virus antibody titers and intensity of infections after renal transplantation
- (2008) Daniel L. Bohl et al. JOURNAL OF CLINICAL VIROLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started